SCHEMBL11516144

SCHEMBL11516144

Nc1ccc(S(=O)(=O)NCCS(=O)(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 1.00
CYP3A4 P08684 1/20 0.66
CA1 P00915 11/20 0.64
CA2 P00918 11/20 0.64
CA9 Q16790 11/20 0.64
CA12 O43570 10/20 0.64
PRMT1 Q99873 1/20 0.57
CA6 P23280 2/20 0.55
CA5A P35218 2/20 0.55
CA7 P43166 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
CA14 Q9ULX7 1/20 0.55
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53
CA4 P22748 1/20 0.50
ALDH1A1 P00352 2/20 0.48
TSHR P16473 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11520559 0.90 CYP2D6 (0.81) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL11682917 0.90 CYP2D6 (0.81) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL14066337 0.82 CYP2D6 (0.70) CYP2D6CA2CA9CA12ALDH1A1
SCHEMBL17703607 0.81 ALDH1A1 (0.69) CYP2D6CA1CA2MMP1MMP2
SCHEMBL3157516 0.81 CYP2D6 (0.69) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL2563975 0.81 CYP3A4 (0.70) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL9444696 0.81 CYP2D6 (0.69) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL30380602 0.81 CYP2D6 (0.68) CYP2D6CYP3A4CA1CA2CA9
SCHEMBL9444716 0.80 CYP2D6 (0.67) CYP2D6CA1CA2CA9CA12
SCHEMBL14628032 0.79 CYP3A4 (1.00) CYP2D6CYP3A4CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148401-A1 Compounds and Methods of Use Thereof for Treating Tumors GEORGETOWN UNIVERSITY 2018-05-31 US disclosed
US-9695108-B2 Compounds and methods of use thereof for treating tumors GEORGETOWN UNIVERSITY (US) 2017-07-04 US disclosed
US-20150344440-A1 Compounds and Methods of Use Thereof for Treating Tumors GEORGETOWN UNIVERSITY 2015-12-03 US disclosed
WO-2014032019-A2 COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING TUMORS GEORGETOWN UNIVERSITY (US) 2014-02-27 WO disclosed
US-4180503-A FOR DYEING POLYAMIDES BAYER AKTIENGESELLSCHAFT (DE) 1979-12-25 US disclosed
US-4124581-A FOR NATURAL AND SYNTHETIC FIBERS, COLORFAST BAYER AKTIENGESELLSCHAFT (DE) 1978-11-07 US disclosed
US-4060521-A POLYAMIDE BAYER AKTIENGESELLSCHAFT (DT) 1977-11-29 US disclosed
US-4055557-A MONOAZO DYES BAYER AKTIENGESELLSCHAFT (DT) 1977-10-25 US disclosed
US-3951944-A Fiber-reactive, water-soluble disazo dyes containing an N-B-sulfoethylamide group HOECHST AKTIENGESELLSCHAFT (DT) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344440-A1 Compounds and Methods of Use Thereof for Treating Tumors VHL, TP53, RHOA CYP2D6 4178/4885CYP3A4 4425/4885CA1 200/4885
US-20180148401-A1 Compounds and Methods of Use Thereof for Treating Tumors VHL, TP53, RHOA CYP2D6 4178/4885CYP3A4 4425/4885CA1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.